<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34532877</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2125</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>88</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of clinical pharmacology</Title>
          <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.</ArticleTitle>
        <Pagination>
          <StartPage>2284</StartPage>
          <EndPage>2296</EndPage>
          <MedlinePgn>2284-2296</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.15087</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Examine relationships between the systemic exposure of acalabrutinib, a highly selective, next-generation Bruton tyrosine kinase inhibitor, and its active metabolite (ACP-5862) vs. efficacy and safety responses in patients with B-cell malignancies who received acalabrutinib as monotherapy or in combination with obinutuzumab.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">For exposure-efficacy analyses, patients with untreated chronic lymphocytic leukaemia were assessed for best overall response, progression-free survival and tumour regression. For exposure-safety analyses, incidences of grade ≥2 adverse events (AEs), grade ≥3 AEs and grade ≥2 events of clinical interest were assessed in patients with B-cell malignancies. Acalabrutinib and ACP-5862 pharmacokinetic (PK) parameter estimates were obtained from population PK modelling. Exposure calculations were based on study dosing regimens. Total active moieties were calculated to account for contributions of ACP-5862 to overall efficacy/safety.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 573 patients were included (exposure-efficacy analyses, n = 274; exposure-safety analyses, n = 573). Most patients (93%) received acalabrutinib 100 mg twice daily. Median total active area under the concentration-time curve (AUC<sub>24h,ss</sub> ) and total active maximal concentration at steady-state (C<sub>max,ss</sub> ) were similar for patients who received acalabrutinib as monotherapy or in combination with obinutuzumab, and for responders and nonresponders. No relationship was observed between AUC<sub>24h,ss</sub> /C<sub>max,ss</sub> and progression-free survival or tumour regression. Acalabrutinib AUC<sub>24h,ss</sub> and C<sub>max,ss</sub> were generally comparable across groups regardless of AE incidence.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">No clinically meaningful correlations between acalabrutinib PK exposure and efficacy and safety outcomes were observed. These data support the fixed acalabrutinib dose of 100 mg twice daily in the treatment of patients with B-cell malignancies.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Edlund</LastName>
            <ForeName>Helena</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-4036-0831</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca, Gothenburg, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buil-Bruna</LastName>
            <ForeName>Núria</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vishwanathan</LastName>
            <ForeName>Karthick</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-6555-8131</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Biostatistics, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raman</LastName>
            <ForeName>Rakesh</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Safety Science, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Kock</LastName>
            <ForeName>Miné</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhongqing</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology Data Services, R&amp;D, AstraZeneca, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baek</LastName>
            <ForeName>Marshall</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Biostatistics, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ware</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tomkinson</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Shringi</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-3120-225X</Identifier>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>7503323</NlmUniqueID>
        <ISSNLinking>0306-5251</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="Y">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ACP-5862</Keyword>
        <Keyword MajorTopicYN="N">B-cell</Keyword>
        <Keyword MajorTopicYN="N">BTK inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Calquence</Keyword>
        <Keyword MajorTopicYN="N">acalabrutinib</Keyword>
        <Keyword MajorTopicYN="N">chronic</Keyword>
        <Keyword MajorTopicYN="N">exposure-efficacy</Keyword>
        <Keyword MajorTopicYN="N">exposure-response</Keyword>
        <Keyword MajorTopicYN="N">exposure-safety</Keyword>
        <Keyword MajorTopicYN="N">leukaemia</Keyword>
        <Keyword MajorTopicYN="N">lymphocytic</Keyword>
        <Keyword MajorTopicYN="N">obinutuzumab</Keyword>
        <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>7</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34532877</ArticleId>
        <ArticleId IdType="doi">10.1111/bcp.15087</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.</Citation>
        </Reference>
        <Reference>
          <Citation>Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240-252.</Citation>
        </Reference>
        <Reference>
          <Citation>Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.</Citation>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204-1213.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019;33(11):2762-2766.</Citation>
        </Reference>
        <Reference>
          <Citation>Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849-2861.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharman JPE, Egyed M, Jurczak W, Skarbnik A, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291.</Citation>
        </Reference>
        <Reference>
          <Citation>Herman SEM, Montraveta A, Niemann CU, et al. The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831-2841.</Citation>
        </Reference>
        <Reference>
          <Citation>Calquence [summary of product characteristics]. Bedfordshire, United Kingdom: AstraZeneca UK Limited; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Barf T, Kaptein A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem. 2012;55(14):6243-6262.</Citation>
        </Reference>
        <Reference>
          <Citation>Podoll T, Pearson PG, Evarts J, et al. Bioavailability, biotransformation, and excretion of the covalent Bruton tyrosine kinase inhibitor acalabrutinib in rats, dogs, and humans. Drug Metab Dispos. 2019;47(2):145-154.</Citation>
        </Reference>
        <Reference>
          <Citation>Edlund H, Bellanti F, Liu H, et al. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach. Br J Clin Pharmacol. 2021. Online ahead of print. https://doi.org/10.1111/bcp.14988</Citation>
        </Reference>
        <Reference>
          <Citation>Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69-71.</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander SPH, Kelly E, Mathie A, et al. The concise guide to PHARMACOLOGY 2019/20: introduction and other protein targets. Br J Pharmacol. 2019;176(Suppl 1):S1-s20.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaptein A, Podoll T, de Bruin G, et al. Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity [poster]. Presented at: Annual Meeting of the American Association for Cancer Research; March 29-April 3, 2019; Atlanta, GA</Citation>
        </Reference>
        <Reference>
          <Citation>Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015;75(1):111-121.</Citation>
        </Reference>
        <Reference>
          <Citation>NDA/BLA Multi-disciplinary review and evaluation NDA 213217 Brukinsa (zanubrutinib). Center for Drug Evaluation and Research. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000MultidisciplineR.pdf. Accessed August 23, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaptein A, de Bruin G, Emmelot-van Hoek M, van de Kar B, de Jong A, Gulrajani M, Demont D, Covey T, Mittag D, Barf T Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies [poster]. Presented at: Annual Meeting of the American Society of Hematology; December 1-4, 2018; San Diego, CA.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical Pharmacology and Biopharmaceutics Review(s): Imbruvica™ (ibrutinib). Center for Drug Evaluation and Research. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf. Accessed August 23, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Gallais F, Ysebaert L, Despas F, et al. Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies. Clin Pharmacokinet. 2020;59(9):1171-1183.</Citation>
        </Reference>
        <Reference>
          <Citation>Ou Y, Wang K, Liu L, Jindal A, Gao Y, Sahasranaman S. Exposure-response relationship of the bruton tyrosine kinase inhibitor, zanubrutinib (BGB-3111) in patients with hematologic malignancies [abstract]. Blood. 2019;134(Suppl 1):5063.</Citation>
        </Reference>
        <Reference>
          <Citation>Sun CCL, Nierman PK, Kendall EK, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136(1):93-105.</Citation>
        </Reference>
        <Reference>
          <Citation>Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.</Citation>
        </Reference>
        <Reference>
          <Citation>Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851-859.</Citation>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: mature results from phase II study demonstrating durable remissions and long-term tolerability [abstract]. Presented at: Annual Meeting of the American Society of Clinical Oncology; May 29-31, 2020; Chicago, Il</Citation>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Blachly JS, Rogers KA, et al. Acalabrutinib plus obinutuzumab in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Cancer Discov. 2020;10(3):394-405.</Citation>
        </Reference>
        <Reference>
          <Citation>Dyer MJS, De Vos S, Ruan J, et al. Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) [abstract]. J Clin Oncol. 2018;36(suppl 15):7547.</Citation>
        </Reference>
        <Reference>
          <Citation>Fowler NH, Coleman M, Stevens DA, et al. Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL) [abstract]. J Clin Oncol. 2018;36(suppl 15):7549.</Citation>
        </Reference>
        <Reference>
          <Citation>Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112-e121.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
